PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(01): 052-059
DOI: 10.1055/s-0042-1742609
Review Article

A Radiologist's Perspective on Treatment-Related Pseudoprogression: Clues and Hues

Authors

  • Nivedita Chakrabarty

    1   Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India

  • Abhishek Mahajan

    1   Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India

  • Akshay D. Baheti 

    1   Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India

  • Amit Choudhari

    1   Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India

  • Vasundhara Patil

    1   Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India

  • Palak Popat

    1   Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India

  • Himangi Unde

    1   Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India

Funding None.
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints
Preview

Abstract

Pseudoprogression refers to the initial apparent increase in tumor burden observed on imaging after cancer therapy, with subsequent delayed response to the same treatment, thus giving a false initial appearance of disease progression. It is essential to differentiate pseudoprogression from true progression to prevent the patients from getting deprived of the benefits of their ongoing cancer therapy owing to their early withdrawal. It also affects their recruitment for clinical trials. Pseudoprogression, albeit uncommon, has been observed after various types of cancer therapy; however, this phenomenon has gained momentum of late due to the emergence of immunotherapy for the treatment of various malignancies. Besides immunotherapy, pseudoprogression has predominantly been of concern in a few patients after radiation therapy for brain tumors and metastasis, after molecular targeted therapy for a variety of tumors, and after chemotherapy in metastatic bone lesions. This article reviews the available data on imaging of pseudoprogression from various types of cancer therapies, highlighting ways to suspect or identify it on imaging.

Keywords

pseudoprogression - immunotherapy - radiation therapy - targeted therapy

Contributions of Each Author

N.C. contributed to the concept, design, definition of intellectual content, literature search, and manuscript preparation. A.M. contributed to manuscript editing and manuscript review. A.D.B. contributed to manuscript review. A.C. contributed to manuscript review. V.P. contributed to manuscript review. P.P. contributed to manuscript review. H.U. contributed to manuscript review.


The manuscript has been read and approved by all the authors and the requirements for authorship have been met, and each author believes that the manuscript represents honest work.




Publikationsverlauf

Artikel online veröffentlicht:
14. Februar 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India